Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03916692 · ClinicalTrials.gov registry record · NA

GRAPE • Glycemic Response of Amylopectin Containing Drinks

A NA study, sponsored by Arizona State University.

Terminated
Registry status
NA
Development phase
15
Enrollment target

NCT03916692: Clinical Trial NA study, sponsored by Arizona State University.

NCT03916692 is a NA study that was terminated before completion, run by Arizona State University. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03916692, a NA study, was terminated before completion, sponsored by Arizona State University.

TERMINATED
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

To quantify the glycemic index of the SP energy-smart-based nutrition supplement and the SP Glucose-support formula as compared to a glucose drink. We hypothesized that both the energy-smart-based nutritional supplement and the SP Glucose-support formula will have low glycemic index. The aim of the study is to quantify the glycemic index of the SP energy-smart-based nutrition supplement and the SP Glucose-support formula as compared to a glucose drink. We hypothesized that both the energy-smart-based nutritional supplement and the SP Glucose-support formula will have low glycemic index.

Primary Outcome

Positive integer of the area under the Curve of glucose

Interventions

  • DIETARY_SUPPLEMENT Carbohydrate drink
  • DIETARY_SUPPLEMENT Energy smart Carbohydrate blend
  • DIETARY_SUPPLEMENT Liquid Dextrose

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-04-23
Est. Completion 2021-08-30
Phase NA
Arizona State University

187 total trials

Why NCT03916692 stopped before completion

NCT03916692 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 3 interventions - of which Carbohydrate drink is the first listed.

NCT03916692 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03916692 about?

NCT03916692 is a clinical study titled "GRAPE • Glycemic Response of Amylopectin Containing Drinks". To quantify the glycemic index of the SP energy-smart-based nutrition supplement and the SP Glucose-support formula as compared to a glucose drink. We hypothesized that both the energy-smart-based nutritional supplement and the SP Glucose-support formula will have low glycemic index. The aim of the...

What is the current status of trial NCT03916692?

This trial is currently terminated. It is a NA study. The enrollment target is 15 participants. The study started on 2019-04-23. Estimated completion is 2021-08-30.

What interventions are being tested in trial NCT03916692?

The interventions under investigation include: Carbohydrate drink (DIETARY_SUPPLEMENT), Energy smart Carbohydrate blend (DIETARY_SUPPLEMENT), Liquid Dextrose (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03916692?

This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03916692's enrollment target sits among peer trials

15 1881st of 2000 higher than 92 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03916692, the US trial registry maintained by the National Library of Medicine. NCT03916692 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.